Iridex Stock Performance
| IRIX Stock | USD 1.32 0.09 6.38% |
IRIDEX has a performance score of 2 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.32, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, IRIDEX's returns are expected to increase less than the market. However, during the bear market, the loss of holding IRIDEX is expected to be smaller as well. IRIDEX currently retains a risk of 4.49%. Please check out IRIDEX treynor ratio, as well as the relationship between the expected short fall and day median price , to decide if IRIDEX will be following its current trending patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in IRIDEX are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating forward indicators, IRIDEX may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
1 | Acquisition by Romeo Dizon of 100 shares of IRIDEX at 1.2 subject to Rule 16b-3 | 05/05/2025 |
2 | Acquisition by Romeo Dizon of 100 shares of IRIDEX at 1.19 subject to Rule 16b-3 | 05/06/2025 |
3 | Acquisition by Romeo Dizon of 193 shares of IRIDEX at 1.15 subject to Rule 16b-3 | 05/07/2025 |
4 | Acquisition by Romeo Dizon of 100 shares of IRIDEX at 1.15 subject to Rule 16b-3 | 05/08/2025 |
5 | Acquisition by Romeo Dizon of 100 shares of IRIDEX at 1.16 subject to Rule 16b-3 | 05/12/2025 |
6 | Acquisition by Romeo Dizon of 100 shares of IRIDEX at 1.0 subject to Rule 16b-3 | 05/23/2025 |
7 | Acquisition by Romeo Dizon of 200 shares of IRIDEX at 0.95 subject to Rule 16b-3 | 05/28/2025 |
8 | Acquisition by Romeo Dizon of 200 shares of IRIDEX at 0.985 subject to Rule 16b-3 | 05/29/2025 |
9 | Acquisition by Romeo Dizon of 100 shares of IRIDEX at 0.99 subject to Rule 16b-3 | 06/03/2025 |
10 | Acquisition by Romeo Dizon of 1500 shares of IRIDEX at 0.97 subject to Rule 16b-3 | 06/06/2025 |
11 | Acquisition by Romeo Dizon of 500 shares of IRIDEX at 0.99 subject to Rule 16b-3 | 06/09/2025 |
12 | Acquisition by Romeo Dizon of 335 shares of IRIDEX at 0.9775 subject to Rule 16b-3 | 06/10/2025 |
13 | Acquisition by Romeo Dizon of 245 shares of IRIDEX at 0.965 subject to Rule 16b-3 | 06/11/2025 |
14 | Acquisition by Moore William M of 20000 shares of IRIDEX at 0.9747 subject to Rule 16b-3 | 06/12/2025 |
15 | Acquisition by Patrick Mercer of 250 shares of IRIDEX at 0.96 subject to Rule 16b-3 | 06/13/2025 |
16 | Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse Technology as an Adjunct to anti-VEGF Therapy... | 06/24/2025 |
17 | Is IRIXs earnings trend improving for investors - AInvest | 07/09/2025 |
| Begin Period Cash Flow | 7 M | |
| Total Cashflows From Investing Activities | -13 K |
IRIDEX Relative Risk vs. Return Landscape
If you would invest 130.00 in IRIDEX on April 27, 2025 and sell it today you would earn a total of 2.00 from holding IRIDEX or generate 1.54% return on investment over 90 days. IRIDEX is currently generating 0.12% in daily expected returns and assumes 4.4933% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than IRIDEX, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
IRIDEX Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IRIDEX's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as IRIDEX, and traders can use it to determine the average amount a IRIDEX's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0267
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | IRIX | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.49 actual daily | 40 60% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average IRIDEX is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IRIDEX by adding it to a well-diversified portfolio.
IRIDEX Fundamentals Growth
IRIDEX Stock prices reflect investors' perceptions of the future prospects and financial health of IRIDEX, and IRIDEX fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IRIDEX Stock performance.
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.0954 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | (0.02) % | ||||
| Current Valuation | 20.22 M | ||||
| Shares Outstanding | 16.79 M | ||||
| Price To Earning | (6.30) X | ||||
| Price To Book | 26.01 X | ||||
| Price To Sales | 0.49 X | ||||
| Revenue | 48.67 M | ||||
| Gross Profit | 20.1 M | ||||
| EBITDA | (6.88 M) | ||||
| Net Income | (8.91 M) | ||||
| Cash And Equivalents | 17.97 M | ||||
| Cash Per Share | 1.12 X | ||||
| Total Debt | 4.64 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.19 X | ||||
| Book Value Per Share | 0.05 X | ||||
| Cash Flow From Operations | (7.29 M) | ||||
| Earnings Per Share | (0.43) X | ||||
| Market Capitalization | 23.67 M | ||||
| Total Asset | 29.14 M | ||||
| Retained Earnings | (88.01 M) | ||||
| Working Capital | 7 M | ||||
| Current Asset | 30.77 M | ||||
| Current Liabilities | 7.43 M | ||||
About IRIDEX Performance
Evaluating IRIDEX's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if IRIDEX has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if IRIDEX has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 122.51 | 188.55 | |
| Return On Tangible Assets | (0.19) | (0.18) | |
| Return On Capital Employed | (0.25) | (0.27) | |
| Return On Assets | (0.18) | (0.17) | |
| Return On Equity | (0.44) | (0.46) |
Things to note about IRIDEX performance evaluation
Checking the ongoing alerts about IRIDEX for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for IRIDEX help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| IRIDEX may become a speculative penny stock | |
| IRIDEX had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 48.67 M. Net Loss for the year was (8.91 M) with profit before overhead, payroll, taxes, and interest of 20.1 M. | |
| IRIDEX currently holds about 17.97 M in cash with (7.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.12. | |
| Roughly 28.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Is IRIXs earnings trend improving for investors - AInvest |
- Analyzing IRIDEX's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IRIDEX's stock is overvalued or undervalued compared to its peers.
- Examining IRIDEX's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IRIDEX's management team can have a significant impact on its success or failure. Reviewing the track record and experience of IRIDEX's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IRIDEX's stock. These opinions can provide insight into IRIDEX's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for IRIDEX Stock Analysis
When running IRIDEX's price analysis, check to measure IRIDEX's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IRIDEX is operating at the current time. Most of IRIDEX's value examination focuses on studying past and present price action to predict the probability of IRIDEX's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IRIDEX's price. Additionally, you may evaluate how the addition of IRIDEX to your portfolios can decrease your overall portfolio volatility.